PLIANT THERAPEUTICS, INC. Deferred Offering Costs
PLIANT THERAPEUTICS, INC. (PLRX) had Deferred Offering Costs of $2.80 million as of 2019-12-31, per its 10-K filed 2021-03-16.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2021-03-16
- 2019-12-31: Deferred Offering Costs $2.80M; Deferred Offering Costs as first filed $2.70M.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2019-12-31 | $2.80M 10-K · filed 2021-03-16 | $2.70M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |